Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Demand for Personalized Medicine
4.2.2 Rising R&D Activities in the Pharmaceutical Industry
4.2.3 Continuous Support for Cancer Research From Public as Well as Private Sector
4.3 Market Restraints
4.3.1 High Cost of Personalized PDX Models
4.3.2 Stringent Regulations Towards Use of Animals Models
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Mice Model
5.1.2 Rats Model
5.2 By Tumor Type
5.2.1 Gastrointestinal Tumor Model
5.2.2 Gynecological Tumor Model
5.2.3 Respiratory Tumor Model
5.2.4 Other Tumor Model
5.3 By End User
5.3.1 Pharmaceutical & Biotechnology Companies
5.3.2 Academic & Research Institutions
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Rest of the World


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Champions Oncology, Inc.
6.1.2 Charles River Laboratories, Inc.
6.1.3 Crown Bioscience, Inc.
6.1.4 EPO Berlin-Buch GmbH
6.1.5 Hera BioLabs
6.1.6 Horizon Discovery Group plc,
6.1.7 Oncodesign
6.1.8 Pharmatest Services Ltd
6.1.9 Urolead
6.1.10 Xentech


7 MARKET OPPORTUNITIES AND FUTURE TRENDS